Mirum Pharmaceuticals Shows Market Leadership With Jump To 84 RS Rating

When looking for the best stocks to buy and watch, focus on those with rising relative price strength.

One stock that fits that bill is Mirum Pharmaceuticals (MIRM), which had its Relative Strength (RS) Rating upgraded from 80 to 84 Monday.

X When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.

IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.

Over 100 years of market history shows that the best-performing stocks often have an 80 or higher RS Rating as they launch their biggest runs.

See How IBD Helps You Make More Money In Stocks

Mirum Pharmaceuticals is building a consolidation with a 30.39 entry. See if it can clear the breakout price in heavy trade.

Mirum Pharmaceuticals showed 0% EPS growth last quarter. Sales increased 115%.

The company earns the No. 107 rank among its peers in the Medical-Biomed/Biotech industry group. Kiniksa Pharmaceuticals (KNSA) and Halozyme Therapeutics (HALO) are also among the group's highest-rated stocks.

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

YOU MAY ALSO LIKE:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Identify Bases And Buy Points With Pattern Recognition From MarketSmith